Condition: Psoriasis · Psoriasis Vulgaris · Sponsor: Radboud University Medical Center
The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| ULB Erasme | Brussels, Belgium | — |
| Ghent University Hospital | Ghent, Belgium | — |
| AZ Maria Middelares | Ghent, Belgium | — |
| AZ St Lucas | Ghent, Belgium | — |
| UCL Saint Luc | Leuven, Belgium | — |
| UZ Leuven | Leuven, Belgium | — |
| CHU Liege | Liège, Belgium | — |
| Dermatologie Maldegem | Maldegem, Belgium | — |
| Ziekenhuisgroep Twente | Almelo, Netherlands | — |
| Bravis hospital | Bergen op Zoom, Netherlands | — |
| Amphia Hospital | Breda, Netherlands | — |
| Slingeland hospital | Doetinchem, Netherlands | — |
+ 7 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.